SCHEMBL7201305

SCHEMBL7201305

CCCN(CCC)c1ccnc2ccnn12

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 19/20 0.43
DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14158421 0.77 DYRK1A (0.40) DYRK1A
SCHEMBL25318530 0.73 CRHR1 (0.47) CRHR1
SCHEMBL9911039 0.69 DGAT1 (0.34) DYRK1A
SCHEMBL20798991 0.68 KDM5A (0.45) CRHR1
SCHEMBL11049763 0.67 KDM5A (0.41)
SCHEMBL4572140 0.66 DGAT1 (0.37) DYRK1A
SCHEMBL5432578 0.66 CRHR1 (0.55) CRHR1
SCHEMBL3285613 0.66 CDK8 (0.42) CRHR1DYRK1A
SCHEMBL19788662 0.66 DGAT1 (0.35)
SCHEMBL23869471 0.66 CCNT1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010041673-A1 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues PFIZER INC. 2001-11-15 US claimed
US-6589947-B1 Treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist. PFIZER INC. 2003-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041673-A1 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues CRH, GHSR, GHRHR CRHR1 4/4885DYRK1A 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.